15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $875M | $264M | 97.8% | 39.0% | $345M | $0 | $90M |
| 2024 | $451M | -$89M | 97.3% | -0.6% | -$53M | $315M | $105M |
| 2023 | $331M | -$227M | 98.6% | -31.3% | -$97M | $303M | $111M |
| 2022 | $271M | -$247M | 97.6% | -54.8% | -$163M | $232M | $305M |
| 2021 | $157M | -$184M | 95.4% | -113.1% | -$145M | $298M | $504M |
| 2020 | $18M | -$183M | 91.3% | -981.1% | -$136M | $123M | $272M |
| 2019 | $49M | -$109M | 92.4% | -203.7% | -$90M | $50M | $114M |
| 2018 | $21M | -$101M | 0.0% | -456.2% | -$93M | $30M | $27M |
| 2017 | $25M | -$66M | 95.5% | -227.9% | -$41M | $23M | $50M |
| 2016 | $26M | -$55M | 91.3% | -184.4% | -$59M | $23M | $22M |
| 2015 | — | -$43M | — | — | -$18M | — | $29M |
| 2014 | — | -$45M | — | — | — | — | $55M |
| 2013 | — | -$30M | — | — | -$27M | — | $21M |
| 2012 | — | -$39M | — | — | -$38M | — | $21M |
| 2011 | — | -$57M | — | — | -$32M | — | $16M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $156M | -$722M | 96.6% | -448.6% | -$62M | $395M | $172M |
| Dec '25 | $407M | $246M | 97.7% | 64.0% | $291M | $0 | $90M |
| Sep '25 | $159M | $13M | 98.6% | 18.6% | $40M | $194M | $84M |
| Jun '25 | $163M | $5M | 98.3% | 18.2% | $41M | $243M | $88M |
| Mar '25 | $146M | $32000 | 96.9% | 14.6% | -$28M | $315M | $105M |
| Dec '24 | $132M | -$27M | 95.4% | -3.4% | -$6M | $315M | $105M |
| Sep '24 | $117M | -$14M | 97.3% | 6.6% | $8M | $314M | $97M |
| Jun '24 | $109M | -$13M | 98.4% | 8.0% | -$2M | $314M | $78M |
| Mar '24 | $93M | -$35M | 98.6% | -15.6% | -$54M | $308M | $84M |
| Dec '23 | $93M | -$62M | 98.3% | -45.7% | -$9M | $303M | $111M |
| Sep '23 | $87M | -$36M | 98.7% | -13.7% | -$21M | $298M | $151M |
| Jun '23 | $82M | -$75M | 98.9% | -25.1% | -$19M | $293M | $146M |
| Mar '23 | $69M | -$53M | 98.6% | -41.3% | -$48M | $233M | $155M |
| Dec '22 | $80M | -$72M | 97.0% | -58.2% | -$24M | $232M | $305M |
| Sep '22 | $76M | -$43M | 95.3% | -23.0% | -$33M | $224M | $247M |
| Jun '22 | $66M | -$59M | 99.6% | -53.0% | -$28M | $145M | $273M |
| Mar '22 | $50M | -$74M | 99.5% | -100.1% | -$78M | $140M | $396M |
| Dec '21 | $47M | -$18M | 99.1% | -110.6% | -$34M | $298M | $504M |
| Sep '21 | $41M | -$59M | 98.6% | -108.8% | -$24M | $132M | $200M |
| Jun '21 | $50M | -$43M | 99.4% | -59.2% | -$26M | $127M | $210M |
How the market has priced BCRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Biocryst Pharmaceuticals Inc's revenue has grown 117.9% per year. These are computed facts, not advice.
As of FY2025, Biocryst Pharmaceuticals Inc reported $0 of total debt against $90M of cash; operating income covered interest expense 4.3×.
In FY2025, gross margin was 97.8%, operating margin 39.0%, and net margin 30.2%.
As of Jun '26, Biocryst Pharmaceuticals Inc traded at a price-to-earnings ratio of about 9.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.